MannKind (MNKD) Posts Q3 Loss of 9c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to MannKind (MNKD) Posts Q3 Loss of 9c/Share
November 5, 2014 3:35 PM EST
Goldman Sachs maintained a Neutral rating on MannKind (NASDAQ: MNKD) with a price target of $6.00. Comments follow Q3 earnings and a related conference call.
Analyst Jay Olson said, "MNKDs 3Q earnings call focused on progression of the Afrezza partnership and commercialization plans. Beyond manufacturing, launch execution is in the hands of a joint steering committee with Sanofi, according to MNKD. As a result, management can only disclose limited details at this point so... More
November 4, 2014 10:28 AM EST
BofA/Merrill Lynch analyst Steve Byrne reiterated an Underperform rating and $4 price target on MannKind (NASDAQ: MNKD) following Q3 earnings and ahead of the Afrezza launch. The analyst notes that on the call the company highlighted that Sanofi is fully committed... More
November 4, 2014 9:34 AM EST
Piper Jaffray analyst Joshua Schimmer lowered his price target on Neutral-rated MannKind (NASDAQ: MNKD) to $7.00 (from $9.50) following in-line Q3 results but notes as the Afrezza launch nears "things are getting more interesting."
Schimmer commented, "Affrezza has yet to launch and won't be a relevant... More
